Neuropace Inc (NPCE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuropace Inc (NPCE) has a cash flow conversion efficiency ratio of -0.408x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.90 Million) by net assets ($14.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Neuropace Inc (NPCE) net asset quality to measure how much of total assets are equity-financed.
Neuropace Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Neuropace Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Neuropace Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Neuropace Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuropace Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chung Hwa Pulp Corp
TW:1905
|
-0.002x |
|
Shanghai SK Petroleum & Chemical Equipment Corp Ltd
SHE:002278
|
-0.008x |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
F:GU5
|
0.050x |
|
Prince Housing & Development Corp
TW:2511
|
0.048x |
|
Mahindra Logistics Limited
NSE:MAHLOG
|
-0.030x |
|
Lindex Group
HE:LINDEX
|
-0.015x |
|
Hankook Shell Oil
KO:002960
|
0.124x |
|
China Merchants Port Group Co Ltd
SHE:201872
|
0.012x |
Annual Cash Flow Conversion Efficiency for Neuropace Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Neuropace Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see NPCE company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $19.03 Million | $-11.01 Million | -0.578x | +74.18% |
| 2024-12-31 | $8.01 Million | $-17.95 Million | -2.240x | -134.83% |
| 2023-12-31 | $20.65 Million | $-19.70 Million | -0.954x | +10.03% |
| 2022-12-31 | $34.78 Million | $-36.87 Million | -1.060x | -217.06% |
| 2021-12-31 | $73.50 Million | $-24.58 Million | -0.334x | -328.75% |
| 2020-12-31 | $-147.83 Million | $-21.61 Million | 0.146x | -24.45% |
| 2019-12-31 | $-129.35 Million | $-25.03 Million | 0.193x | -- |
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more